Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amgen reports positive results from Phase II study of bone cancer drug
Interim results from the 12-month, open-label Phase II study show that 120mg of denosumab, administered subcutaneously once monthly with a loading dose at days 8 and 15 of
Interim results from the 12-month, open-label Phase II study show that 120mg of denosumab, administered subcutaneously once monthly with a loading dose at days 8 and 15 of
These new collaborations center on the Locus p38 inhibitor portfolio of drug development candidates, and will build upon an existing research relationship with Cancer Therapy & Research Center
The company is releasing the new Goodnak formulations in partnership with JJB, the subsidiary of AMDL’s Chinese subsidiary Jade Pharmaceutical. Scheduled to be released in June, 2008, the
MapQuant Dx Genomic Grade is a molecular diagnostic test to accurately measure tumor grade, a consensus indicator of tumor proliferation, risk of metastasis and response to chemotherapy. According
In this Roche-sponsored, placebo-controlled Phase III trial (Avado), two dose levels of Avastin in combination with docetaxel chemotherapy showed a statistically significant improvement in progression-free survival (PFS) compared
Lupin’s Topiramate tablets are the AB-rated generic equivalent of Ortho-McNeil’s Topamax tablets, indicated for the treatment of seizures. The product will be introduced in the market through LPI’s
Among 43 patients currently evaluable of the 50 patients enrolled, tumors injected with OncoVEX GM-CSF routinely responded, often with local complete responses or palliative benefit. With regard to
Nexium IV for Injection is indicated for the short-term treatment of gastroesophageal reflux disease adult patients with a history of erosive esophagitis, as an alternative to oral therapy
The data showed that RTA 402 had an excellent safety profile and provided a clinical benefit in a significant percentage of patients. Investigators also confirmed that the drug
The randomized, controlled, 100-patient Phase II study is comparing the safety and efficacy of intravenous picoplatin given once every four weeks in combination with 5-fluorouracil and leucovorin in